utilisation < utility < utilization

Facettes : Author.f AffPays.f AffRegion.f AffVille.f AffOrg.f KwdFr.f Mesh.f MeshFr.f Teeft.f

List of bibliographic references indexed by utility

Number of relevant bibliographic references: 25.
[0-20] [0 - 20][0 - 25][20-24][20-40]

Ident.	Authors (with country if any)	Title
000018 (2020)	Emily Liang [États-Unis] ; Mihaela Taylor [États-Unis] ; Maureen Mcmahon [États-Unis]	Utility of the AVISE Connective Tissue Disease test in predicting lupus diagnosis and progression
000396 (2020)	Patricia Ruiz-Limon [Espagne] ; Maria Lourdes Ladehesa-Pineda [Espagne] ; Maria Del Carmen Castro-Villegas [Espagne] ; Maria Del Carmen Abalos-Aguilera [Espagne] ; Clementina Lopez-Medina [Espagne] ; Chary Lopez-Pedrera [Espagne] ; Nuria Barbarroja [Espagne] ; Daniel Espejo-Peralbo [Espagne] ; Jose Antonio Gonzalez-Reyes [Espagne] ; Jose Manuel Villalba [Espagne] ; Carlos Perez-Sanchez [Espagne] ; Alejandro Escudero-Contreras [Espagne] ; Eduardo Collantes-Estevez [Espagne] ; Pilar Font-Ugalde [Espagne] ; Yolanda Jimenez-Gomez [Espagne]	Enhanced NETosis generation in radiographic axial spondyloarthritis: utility as biomarker for disease activity and anti-TNF-α therapy effectiveness
000459 (2020)	Benjamin Birkner [Allemagne] ; Jürgen Rech [Allemagne] ; Tom Stargardt [Allemagne]	Cost-utility analysis of de-escalating biological disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis
000650 (2019)	Toshiyuki Yano ; Arata Osanami ; Masaki Shimizu ; Satoshi Katano ; Nobutaka Nagano ; Hidemichi Kouzu ; Masayuki Koyama ; Atsuko Muranaka ; Ryo Harada ; Hirosato Doi ; Nobuyoshi Kawaharada ; Tetsuji Miura	Utility and safety of tocilizumab in Takayasu arteritis with severe heart failure and muscle wasting
000A01 (2019)	Hajime Yoshifuji [Japon]	Pathophysiology of large vessel vasculitis and utility of interleukin-6 inhibition therapy.
001557 (2017)	Shuntaro Saito [Japon] ; Yuko Kaneko [Japon] ; Keisuke Izumi [Japon] ; Tsutomu Takeuchi [Japon]	Utility of Dose Frequency Adjustment in Tocilizumab Administration for Rheumatoid Arthritis.
001838 (2017)	Tanja Schj Dt J Rgensen [Danemark] ; Carl Turesson [Suède] ; Meliha Kapetanovic [Suède] ; Martin Englund [Suède] ; Aleksandra Turkiewicz [Suède] ; Robin Christensen [Danemark] ; Henning Bliddal [Danemark] ; Pierre Geborek [Suède] ; Lars Erik Kristensen [Danemark]	EQ-5D utility, response and drug survival in rheumatoid arthritis patients on biologic monotherapy: A prospective observational study of patients registered in the south Swedish SSATG registry.
001B83 (2016)	Anders Gülfe [Suède] ; Johan K. Wallman [Suède] ; Lars Erik Kristensen [Danemark]	EuroQol-5 dimensions utility gain according to British and Swedish preference sets in rheumatoid arthritis treated with abatacept, rituximab, tocilizumab, or tumour necrosis factor inhibitors: a prospective cohort study from southern Sweden.
002072 (2015)	Kostas Athanasakis [Grèce] ; Filippos Tarantilis ; Konstantina Tsalapati ; Thomais Konstantopoulou ; Eleni Vritzali ; John Kyriopoulos	Cost-utility analysis of tocilizumab monotherapy in first line versus standard of care for the treatment of rheumatoid arthritis in Greece.
002282 (2014)	K. Takase [Royaume-Uni] ; S C Horton [Royaume-Uni] ; A. Ganesha [Royaume-Uni] ; S. Das [Royaume-Uni] ; A. Mchugh [Royaume-Uni] ; P. Emery [Royaume-Uni] ; S. Savic [Royaume-Uni] ; M H Buch [Royaume-Uni]	What is the utility of routine ANA testing in predicting development of biological DMARD-induced lupus and vasculitis in patients with rheumatoid arthritis? Data from a single-centre cohort.
002475 (2014)	Yasuaki Okuda [Japon] ; Makoto Ohnishi ; Kenichiro Matoba ; Kazuo Jouyama ; Akihiro Yamada ; Naoya Sawada ; Sho Mokuda ; Yousuke Murata ; Kiyoshi Takasugi	Comparison of the clinical utility of tocilizumab and anti-TNF therapy in AA amyloidosis complicating rheumatic diseases.
002540 (2014)	Caroline Whately-Smith [Royaume-Uni] ; Claire Watkins [Royaume-Uni] ; Helen Mann [Royaume-Uni] ; Chrissie Fletcher [Royaume-Uni] ; Pierre Ducournau [Suisse]	Utility values in health technology assessments: a statistician's perspective
002541 (2014)	Andrew T. Chow [États-Unis] ; Justin C. Earp [États-Unis] ; Manish Gupta [États-Unis] ; William Hanley [États-Unis] ; Chuanpu Hu [États-Unis] ; Diane D. Wang [États-Unis] ; Stefan Zajic [États-Unis] ; Min Zhu [États-Unis]	Utility of population pharmacokinetic modeling in the assessment of therapeutic protein‐drug interactions
002936 (2013)	B. Y. Hanaoka ; L. C. Cleary ; D. Long ; G. S. Chleboun [États-Unis] ; C. A. Peterson ; C. P. Starnes ; L. J. Crofford	THU0449 Utility of Ultrasound (US) in Assessing Skeletal Muscle Architecture in Idiopathic Inflammatory Myopathies (IIM)
002947 (2013)	A. M. Istrate [Espagne] ; E. De Miguel [Espagne] ; I. Felea [Espagne] ; M. Caracuel Ruíz [Espagne] ; E. Collantes-Estevéz [Espagne]	THU0411 Utility of ultrasound scores in assessment enthesitis on anti-TNF therapy of spondyloarthritis patients
002991 (2013)	T. Hallinen [Finlande] ; E. J. Soini [Finlande] ; A. Diamantopoulos [Royaume-Uni] ; F. Dejonckheere [Suisse] ; V. Vihervaara ; A. Hautala ; K. Aalto [Finlande]	THU0305 Cost-utility of tocilizumab in the treatment of systemic juvenile idiopathic arthritis in finland
002A44 (2013)	Y. Okuda [Japon] ; M. Ohnishi [Japon] ; K. Takasugi [Japon]	THU0091 Comparison of the clinical utility of anti-IL-6 receptor antibody therapy and anti-TNF therapy in aa amyloidosis in rheumatic disease
002D77 (2013)	C. Gibbons ; A. Diamantopoulos [Royaume-Uni] ; H. Pang ; C. Huertas ; F. Dejonckheere [Suisse]	FRI0414 Tocilizumab in methotrexate-intolerant or contraindicated patients – a cost-utility model for scotland
002F98 (2013)	M. Nu Ez ; E. Nu Ez ; S. Sastre ; J. Segur ; L. Lozano ; C. Nicodemo [Espagne] ; F. Maculé ; A. Saul [Espagne]	AB0780 Cost utility analysis of total knee replacement in obese patients with osteoarthritis. prospective study with 12 months follow up
003100 (2013)	M. Kamiya ; S. Soen ; H. Kikuchi [Japon]	AB0556 The utility to measure markers of new bone and cartilage metabolism (DKK-1, OPG, CTX-II) in patients treated with tocilizumab: A multicentre, prospective study
003249 (2013)	K. Takase [Royaume-Uni] ; S. C. Horton [Royaume-Uni] ; A. Ganesha [Royaume-Uni] ; S. Das [Royaume-Uni] ; P. Emery [Royaume-Uni] ; S. Savic [Royaume-Uni] ; M. H. Buch [Royaume-Uni]	AB0274 What is the utility of routine ana testing in predicting development of biological dmard-induced lupus/vasculitis in patients with rheumatoid arthritis?

---

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/TocilizumabV1/Data/Main/Exploration

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/Title.i -k "utility" 

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/Title.i  \
                -Sk "utility" \
         | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd 

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    TocilizumabV1
   |flux=    Main
   |étape=   Exploration
   |type=    indexItem
   |index=    Title.i
   |clé=    utility
}}

---

This area was generated with Dilib version V0.6.34. Data generation: Fri May 22 09:34:00 2020. Site generation: Sun Mar 28 09:01:19 2021